{"name":"Hypera Pharma","slug":"hypera","ticker":"HYPE3.SA","exchange":"B3 (São Paulo)","domain":"hypera.com.br","description":"Hypera Pharma is a Brazilian multinational pharmaceutical \ncompany and is the largest Brazilian pharmaceutical company by market capitalization. Headquartered in São Paulo, its business include pharmaceuticals, consumer healthcare and cosmetics products, and biotechnology products.","hq":"São Paulo, Brazil","founded":1998,"employees":"10564","ceo":"Breno de Oliveira","sector":"Branded Generics / OTC / Consumer Health","stockPrice":23.45,"stockChange":0.88,"stockChangePercent":3.9,"marketCap":"$3.3B","metrics":{"revenue":1545487892.0504525,"revenueGrowth":48.1,"grossMargin":59,"rdSpend":0,"netIncome":240091536.26016,"cash":330317160.9114125,"dividendYield":4.67,"peRatio":9,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2028-06-01","label":"Captopril patent cliff ($10.5M at risk)","drug":"Captopril","type":"patent_expiry","sentiment":"negative"},{"date":"2029-06-01","label":"Enalapril patent cliff ($8.2M at risk)","drug":"Enalapril","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-28","type":"earnings","headline":"Hypera Pharma Reports Strong Q4 2023 Earnings","summary":"Hypera Pharma announced strong Q4 2023 earnings, driven by growth in its branded generics and OTC segments.","drugName":"","sentiment":"positive"},{"date":"2023-11-15","type":"deal","headline":"Hypera Pharma Partners with Local Distributor for Expanded Reach","summary":"Hypera Pharma announced a partnership with a local distributor to expand its reach in the Brazilian market.","drugName":"","sentiment":"neutral"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxQSjlhaHdrMzN2eWdtNThOTzhKU3Bkdzg2UC1WeUNIRmZ5Rk1jRWFYOFo5cDVzaXNsdXVLQ1VsUl9Fd1BETE51VDE1b1VzQllJNzFBaHZqU3MtNkllWGpKQ3hoZVl3SlVpVjlQaVlnOFRTdEVKSnV6a1pTQnN5cDl4VUZmY3RYMUczZExaT3ZCNElrOGQ2ZFg4S3BvVG92TkRtSlNQNlM3NnZ3V2V1MEw2Ylpqamw?oc=5","date":"2026-04-03","type":"pipeline","source":"AD HOC NEWS","summary":"Hypera S.A. stock: Brazil's pharma powerhouse worth your watch? - AD HOC NEWS","headline":"Hypera S.A. stock: Brazil's pharma powerhouse worth your watch?","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-08-10","type":"pipeline","source":"simplywall.st","summary":"Hypera S.A. Just Beat EPS By 8.0%: Here's What Analysts Think Will Happen Next - simplywall.st","headline":"Hypera S.A. Just Beat EPS By 8.0%: Here's What Analysts Think Will Happen Next","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixAFBVV95cUxOSjV4S25BUURPMVpHWlE0UkxrT3VXU0txT0xlc1N4NC1jVzNRR19WRVdBblU2WVRHVVRzWk9GYTlsREV3VUxzMGMxUUl2Vm5VTFdmeno5dUdBV3dvX0JlbkFrUmc0X1RRVExZOEs1c2Q2eldUdFZFUUpXWjczc01GNDdpbVBlbUN4aG9YMmhGTjVWNGRCVGNKNjI5bG5Fby1Td0lhNEZ6QktQR2RRLTZDWTJ6Z2ZHZUQ4RjBmUnEwMTZxc2Nt?oc=5","date":"2025-03-21","type":"patent","source":"Reuters","summary":"Brazil's Hypera to launch an Ozempic generic in 2026, CEO says - Reuters","headline":"Brazil's Hypera to launch an Ozempic generic in 2026, CEO says","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-03-11","type":"pipeline","source":"Valor International","summary":"Votorantim increases stake in Hypera Pharma - Valor International","headline":"Votorantim increases stake in Hypera Pharma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxOUzRkUThmS3lxQzJMVGY0LXhCcjNXcEdHVnpfQlN2eWNENmFERFkyZ0J4enExeWpjQmF3NmYtZHBvRUgzY3pNS3ZEMmd1VFZRa3pROTRwNkJxOWxua2xCMmZHc012dGhJNzRMN2w5UVpOYUdXLTFkWmZ3MEdtQVhEd0Zwc3ZieDlvNFZn?oc=5","date":"2023-04-18","type":"deal","source":"Yahoo Finance","summary":"Clever Leaves Expands Presence in Brazil Through Partnership with Hypera Pharma - Yahoo Finance","headline":"Clever Leaves Expands Presence in Brazil Through Partnership with Hypera Pharma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiY0FVX3lxTE9YLVFwRkZJaGNka3JQeGpwTkM0WWNxc2lyM2FKaHpVZ29SQV9TZlc3Q3hKWHhUYno2NkdHTGpWVGppQ2huWTBGNS1GWWVOUlVvYzh6ZzJGVHZCRWpzdTJrUWQtaw?oc=5","date":"2017-07-21","type":"pipeline","source":"TradingView","summary":"HYPE3 Stock Price and Chart — BMFBOVESPA:HYPE3 - TradingView","headline":"HYPE3 Stock Price and Chart — BMFBOVESPA:HYPE3","sentiment":"neutral"}],"patents":[{"drugName":"Captopril","drugSlug":"captopril","patentNumber":"","type":"Patent Cliff","expiryDate":"2028-06-01","territory":"US","annualRevenue":10500000},{"drugName":"Enalapril","drugSlug":"enalapril","patentNumber":"","type":"Patent Cliff","expiryDate":"2029-06-01","territory":"US","annualRevenue":8199999.999999999}],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Ferrer Internacional","Eurofarma Laboratorios","Bayer"],"therapeuticFocus":["Cardiovascular","Respiratory"],"financials":{"source":"yahoo_finance","revenue":1545487893.6563299,"revenuePeriod":"2025-12-31","revenueHistory":[{"period":"2025-12-31","value":1545487893.6563299},{"period":"2024-12-31","value":1493961105.34554},{"period":"2023-12-31","value":1588746420.08602},{"period":"2022-12-31","value":1514815231.55495}],"grossProfit":912440938.53783,"grossProfitHistory":[{"period":"2025-12-31","value":912440938.53783},{"period":"2024-12-31","value":879418476.1553099},{"period":"2023-12-31","value":1002778976.22136},{"period":"2022-12-31","value":955803044.06756}],"rdSpend":27045386.25308,"rdSpendHistory":[{"period":"2025-12-31","value":27045386.25308},{"period":"2024-12-31","value":29212116.496939998},{"period":"2023-12-31","value":34025734.36314},{"period":"2022-12-31","value":31995302.973789997}],"sgaSpend":456088084.74086,"operatingIncome":348886727.21981,"operatingIncomeHistory":[{"period":"2025-12-31","value":348886727.21981},{"period":"2024-12-31","value":360473133.52661},{"period":"2023-12-31","value":501418795.37542},{"period":"2022-12-31","value":493674852.5046}],"netIncome":239952025.65061,"netIncomeHistory":[{"period":"2025-12-31","value":239952025.65061},{"period":"2024-12-31","value":269183211.9431},{"period":"2023-12-31","value":330802739.7324},{"period":"2022-12-31","value":340585946.31893}],"eps":1.870757,"epsHistory":[{"period":"2025-12-31","value":1.870757},{"period":"2024-12-31","value":2.05963},{"period":"2023-12-31","value":2.557543},{"period":"2022-12-31","value":2.62778}],"cash":330317162.51729,"cashHistory":[{"period":"2025-12-31","value":330317162.51729},{"period":"2024-12-31","value":349143266.15363},{"period":"2023-12-31","value":518074756.27817},{"period":"2022-12-31","value":574597630.28837}],"totalAssets":5050084133.95876,"totalLiabilities":2536007801.6247,"totalDebt":1874349930.4058099,"equity":2513605609.48601,"operatingCashflow":516777608.71138996,"operatingCashflowHistory":[{"period":"2025-12-31","value":516777608.71138996},{"period":"2024-12-31","value":509785617.98930997},{"period":"2023-12-31","value":480958912.09717},{"period":"2022-12-31","value":409256480.82917}],"capex":-160459683.26778,"capexHistory":[{"period":"2025-12-31","value":-160459683.26778},{"period":"2024-12-31","value":-155020776.84223},{"period":"2023-12-31","value":-163139692.11396998},{"period":"2022-12-31","value":-303000182.22863996}],"freeCashflow":356317925.44361,"dividendsPaid":-126018227.36164999,"buybacks":-4634562.52272,"employees":10564,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":111306381.93155,"ebit":112105105.26306,"ebitda":128955578.08042,"period":"2026-03-31","revenue":405038041.31882,"epsBasic":0.54812,"netIncome":69730815.14282,"rdExpense":7548226.54807,"epsDiluted":0.54247,"grossProfit":243001988.53046998,"operatingIncome":101549672.3241},{"sga":118086999.02506,"ebit":142128591.37698,"ebitda":158586025.67132,"period":"2025-12-31","revenue":449056950.75422996,"epsBasic":0.702771,"netIncome":90529137.10841,"rdExpense":8506935.427509999,"epsDiluted":0.702771,"grossProfit":276636892.45217997,"operatingIncome":130536363.76416999},{"sga":null,"ebit":null,"ebitda":null,"period":"2025-09-30","revenue":null,"epsBasic":0.712669,"netIncome":null,"rdExpense":null,"epsDiluted":0.712669,"grossProfit":null,"operatingIncome":null},{"sga":107980408.85294,"ebit":137939057.66199,"ebitda":153745710.09135,"period":"2025-06-30","revenue":432369875.97453,"epsBasic":0.668177,"netIncome":85651284.14141,"rdExpense":7919585.72457,"epsDiluted":0.662466,"grossProfit":259968686.73334,"operatingIncome":129142462.07681},{"sga":113929984.32985,"ebit":-36739868.10663,"ebitda":-21179316.40721,"period":"2025-03-31","revenue":216975330.82914,"epsBasic":-0.22155,"netIncome":-28092217.661429998,"rdExpense":9291808.06541,"epsDiluted":-0.22155,"grossProfit":102427485.12347,"operatingIncome":-45141016.35251},{"sga":120670053.01597999,"ebit":13455246.2707,"ebitda":28485055.449759997,"period":"2024-12-31","revenue":303308309.97779,"epsBasic":null,"netIncome":15970050.46702,"rdExpense":4468554.93409,"epsDiluted":null,"grossProfit":157865789.6036,"operatingIncome":10279623.4749}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":23.45,"previousClose":22.57,"fiftyTwoWeekHigh":28.87,"fiftyTwoWeekLow":20.66,"fiftyTwoWeekRange":"20.66 - 28.87","fiftyDayAverage":22.75,"twoHundredDayAverage":23.57,"beta":0.17,"enterpriseValue":4442971930.565243,"forwardPE":7.3,"priceToBook":1.19,"priceToSales":2.14,"enterpriseToRevenue":2.88,"enterpriseToEbitda":11.33,"pegRatio":0,"ebitda":392210301.3243251,"ebitdaMargin":25.4,"freeCashflow":153419166.13880062,"operatingCashflow":516777603.8937574,"totalDebt":1910252821.572526,"debtToEquity":76,"currentRatio":1.47,"returnOnAssets":4.4,"returnOnEquity":9.7,"analystRating":"2.1 - Buy","recommendationKey":"buy","numberOfAnalysts":13,"targetMeanPrice":29.38,"targetHighPrice":35,"targetLowPrice":24.5,"dividendRate":1.05,"payoutRatio":0.43,"fiveYearAvgDividendYield":4.04,"exDividendDate":1775001600,"insiderHeldPercent":47.9,"institutionHeldPercent":35.3,"sharesOutstanding":703992255,"floatShares":252871258,"sharesShort":0,"shortRatio":0,"shortPercentOfFloat":0,"epsTrailing":2.62,"epsForward":3.22,"revenuePerShare":12.17,"bookValue":19.78,"officers":[{"age":50,"name":"Mr. Breno Toledo Pires de Oliveira","title":"Chief Executive Officer"},{"age":38,"name":"Mr. Ramon Sanches Frutuoso Silva","title":"CFO & Investor Relation Officer"},{"age":40,"name":"Mr. Rafael Vito Batista","title":"Chief Operations Officer"},{"age":54,"name":"Mr. Luiz Eduardo Sales Clavis","title":"Vice President of Commercial & Marketing"},{"age":null,"name":"Mauricio  Christovam","title":"Senior Human Resources Officer"},{"age":null,"name":"Mr. Hélio  Segouras","title":"Head of Consumer Health"}],"industry":"Drug Manufacturers - Specialty & Generic","irWebsite":"http://hypermarcas.infoinvest.com.br/?idioma=enu","website":"https://www.hypera.com.br","phone":""}}